All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer type (metastatic) cancer type (recurrent) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IIIa stage IIIb stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
lung cancer : non small cell (NSCLC), immune chekpoint inhibitors vs. EGFR gene alteration, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CAURAL (EXPLORATORY), 2019 2.60 [0.39; 17.16]
2.60 [0.39 ; 17.16 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable progression or deaths (PFS)detailed results CAURAL (EXPLORATORY), 2019 1.10 [0.22; 5.61]
1.10 [0.22 ; 5.61 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable objective responses (ORR)detailed results CAURAL (EXPLORATORY), 2019 0.45 [0.08; 2.40]
0.45 [0.08 ; 2.40 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable AE (any grade)detailed results CAURAL (EXPLORATORY), 2019 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 12.38 [1.29; 118.34]
12.38 [1.29 ; 118.34 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable AE leading to death (grade 5)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable SAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 1.64 [0.32; 8.45]
1.64 [0.32 ; 8.45 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable STRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 0.33 [0.01; 10.81]
0.33 [0.01 ; 10.81 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable TRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 2.33 [0.41; 13.17]
2.33 [0.41 ; 13.17 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable TRAE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 7.08 [0.34; 148.71]
7.08 [0.34 ; 148.71 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Arthralgia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Back pain AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Constipation AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Cough AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 1.44 [0.04; 46.58]
1.44 [0.04 ; 46.58 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Dry skin AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Nausea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Neutropenia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70]
3.07 [0.13 ; 74.70 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Pneumonia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70]
3.07 [0.13 ; 74.70 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Pruritus AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Rash AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable Stomatitis AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
0.70 [0.01 ; 37.74 ] CAURAL (EXPLORATORY), 2019 1 0% 29 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 22:14 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743